Sjogren's Syndrome Support Group
Sjogren's syndrome is an autoimmune disorder in which immune cells attack and destroy the exocrine glands that produce tears and saliva. It also associated with rheumatic disorders such as rheumatoid arthritis, and it is rheumatoid factor positive in 90 percent of cases.
Will Rheumies being prescribing this for us , I am wondering?
(Human Genome Sciences and GlaxoSmithKline)
Scheduled for a March 10 approval, Benlysta could be the first new lupus drug developed in 50 years.
It isn't a cure. Taken monthly, the intravenous drug prevents flare-ups by inhibiting B-cells found in the immune system, which in lupus patients attack the body and organs.
Lupus isn't easy to treat, which explains why Benlysta has received widespread attention and why Human Genome Sciences' stock price has skyrocketed over the last two years.
Regulators have concerns about Benlysta's long-term effectiveness and the drug's effectiveness on African Americans. The FDA has delayed approval once already. And Human Genome Sciences has warned investors that sales will ramp up slowly.
Still, sales could reach $2.6 billion annually by 2015, says Sanford C. Bernstein analyst Geoff Porges.
(Human Genome Sciences and GlaxoSmithKline)
Scheduled for a March 10 approval, Benlysta could be the first new lupus drug developed in 50 years.
It isn't a cure. Taken monthly, the intravenous drug prevents flare-ups by inhibiting B-cells found in the immune system, which in lupus patients attack the body and organs.
Lupus isn't easy to treat, which explains why Benlysta has received widespread attention and why Human Genome Sciences' stock price has skyrocketed over the last two years.
Regulators have concerns about Benlysta's long-term effectiveness and the drug's effectiveness on African Americans. The FDA has delayed approval once already. And Human Genome Sciences has warned investors that sales will ramp up slowly.
Still, sales could reach $2.6 billion annually by 2015, says Sanford C. Bernstein analyst Geoff Porges.
Would this drug just be used for Lupus or all sorts of autoimmune disorders? Do you know?
It looks promising ...for us with other organs getting affected.
Expense and side effects are two concerns. If they do 2.6b annually I will buy some stock too. (wink) I am going to look deeper into this drug. I have a rheumy appoint in March.